» Articles » PMID: 31191521

Maternal Antibody and ASD: Clinical Data and Animal Models

Overview
Journal Front Immunol
Date 2019 Jun 14
PMID 31191521
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past several decades there has been an increasing interest in the role of environmental factors in the etiology of neuropsychiatric and neurodevelopmental disorders. Epidemiologic studies have shifted from an exclusive focus on the identification of genetic risk alleles for such disorders to recognizing and understanding the contribution of xenobiotic exposures, infections, and the maternal immune system during the prenatal and early post-natal periods. In this review we discuss the growing literature regarding the effects of maternal brain-reactive antibodies on fetal brain development and their contribution to the development of neuropsychiatric and neurodevelopmental disorders. Autoimmune diseases primarily affect women and are more prevalent in mothers of children with neurodevelopmental disorders. For example, mothers of children with Autism Spectrum Disorder (ASD) are significantly more likely to have an autoimmune disease than women of neurotypically developing children. Moreover, they are four to five times more likely to harbor brain-reactive antibodies than unselected women of childbearing age. Many of these women exhibit no apparent clinical consequence of harboring these antibodies, presumably because the antibodies never access brain tissue. Nevertheless, these maternal brain-reactive antibodies can access the fetal brain, and some may be capable of altering brain development when present during pregnancy. Several animal models have provided evidence that exposure to maternal brain-reactive antibodies can permanently alter brain anatomy and cause persistent behavioral or cognitive phenotypes. Although this evidence supports a contribution of maternal brain-reactive antibodies to neurodevelopmental disorders, an interplay between antibodies, genetics, and other environmental factors is likely to determine the specific neurodevelopmental phenotypes and their severity. Additional modulating factors likely also include the microbiome, sex chromosomes, and gonadal hormones. These interactions may help to explain the sex-bias observed in neurodevelopmental disorders. Studies on this topic provide a unique opportunity to learn how to identify and protect at risk pregnancies while also deciphering critical pathways in neurodevelopment.

Citing Articles

Impact of Infections During Pregnancy on Transplacental Antibody Transfer.

Coler C, King-Nakaoka E, Every E, Chima S, Vong A, Del Rosario B Vaccines (Basel). 2024; 12(10.

PMID: 39460363 PMC: 11512415. DOI: 10.3390/vaccines12101199.


Mendelian Randomization Research on the Relationship Between Rheumatoid Arthritis and Systemic Lupus Erythematosus and the Risk of Autistic Spectrum Disorder.

Lee Y, Song G J Rheum Dis. 2023; 29(1):46-51.

PMID: 37476700 PMC: 10324916. DOI: 10.4078/jrd.2022.29.1.46.


Maternal Immune Dysregulation and Autism-Understanding the Role of Cytokines, Chemokines and Autoantibodies.

McLellan J, Kim D, Bruce M, Ramirez-Celis A, Van de Water J Front Psychiatry. 2022; 13:834910.

PMID: 35722542 PMC: 9201050. DOI: 10.3389/fpsyt.2022.834910.


Maternal autoantibody profiles as biomarkers for ASD and ASD with co-occurring intellectual disability.

Ramirez-Celis A, Croen L, Yoshida C, Alexeeff S, Schauer J, Yolken R Mol Psychiatry. 2022; 27(9):3760-3767.

PMID: 35618885 PMC: 9708563. DOI: 10.1038/s41380-022-01633-4.


Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?.

Robinson-Agramonte M, Garcia E, Fraga Guerra J, Vega Hurtado Y, Antonucci N, Semprun-Hernandez N Int J Mol Sci. 2022; 23(6).

PMID: 35328471 PMC: 8955336. DOI: 10.3390/ijms23063033.


References
1.
Comi A, Zimmerman A, Frye V, Law P, Peeden J . Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999; 14(6):388-94. DOI: 10.1177/088307389901400608. View

2.
Carrel L, Cottle A, Goglin K, Willard H . A first-generation X-inactivation profile of the human X chromosome. Proc Natl Acad Sci U S A. 1999; 96(25):14440-4. PMC: 24455. DOI: 10.1073/pnas.96.25.14440. View

3.
Poliak S, Gollan L, Martinez R, Custer A, Einheber S, Salzer J . Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron. 2000; 24(4):1037-47. DOI: 10.1016/s0896-6273(00)81049-1. View

4.
Nilsen J, Mor G, Naftolin F . Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol. 2000; 43(1):64-78. DOI: 10.1002/(sici)1097-4695(200004)43:1<64::aid-neu6>3.0.co;2-7. View

5.
Butler M, Hayashi A, Ohkoshi N, Villmann C, Becker C, Feng G . Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron. 2000; 26(2):307-12. DOI: 10.1016/s0896-6273(00)81165-4. View